Categories: HealthcareNews

WW International, Inc. Announces Participation in Upcoming Investor Conferences

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced that it will present at the following investor conferences.

Baird 2023 Global Healthcare Conference
Tuesday, September 12, 2023 at 4:55 pm ET
New York, NY
Presenters: Heather Stark, Chief Financial Officer and Gary Foster, PhD, Chief Scientific Officer

Morgan Stanley 21st Annual Global Healthcare Conference
Wednesday, September 13, 2023 at 3:35 pm ET
New York, NY
Presenters: Sima Sistani, Chief Executive Officer and Heather Stark, Chief Financial Officer

The presentations will be accessible via live audio webcast on the Company’s corporate website at corporate.ww.com in the Investors section under Presentations and Events. An archive of the webcasts will be available on this site for 30 days.

About WW International, Inc.
WeightWatchers is a human-centric technology company powered by our proven, science-based, clinically effective weight loss and weight management program. For six decades, we have inspired millions of people to adopt healthy habits for real life. We combine technology and community to help members reach and sustain their goals on our program. To learn more about the WeightWatchers approach to healthy living, please visit ww.com. For more information about our global business, visit our corporate website at corporate.ww.com.

For more information, contact:
Corey Kinger
corey.kinger@ww.com

Staff

Recent Posts

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”,…

11 mins ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C…

11 mins ago

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001)…

11 mins ago

American College of Osteopathic Family Physicians Conclave of Fellows Welcomes 2024 Class

CHICAGO, IL / ACCESSWIRE / April 5, 2024 / The American College of Osteopathic Family…

2 days ago

Defence Therapeutics Announces Warrant Terms Amendment

Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…

2 days ago